Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Evolus (EOLS) stock in plain English

Free brief · no signupStart here
EOLSPublished Nov 17, 2026
Evolus Inc
Healthcare · Drug Manufacturers - Specialty & Generic
Sells Jeuveau, an injectable botulinum toxin type A designed specifically for aesthetic facial treatments.
Assets:
Jeuveau neurotoxinFlagship proprietary aesthetic botulinum formulation
Daewoong partnershipExclusive supply agreement with a South Korean manufacturer
Evolysse filler lineDistribution pipeline for next-generation hyaluronic acid fillers
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

49
OPS ScoreOperating finances
Latest quote
-0.99%$7.00
$463.32M
n/a (loss)
$326.28M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 17, 2026Quotes updated Nov 20, 04:10 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was EOLS. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Evolus (EOLS) do?

Evolus Inc (EOLS) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Sells Jeuveau, an injectable botulinum toxin type A designed specifically for aesthetic facial treatments. Evolus focuses exclusively on cash-pay aesthetic neurotoxins and dermal fillers sold directly to medical practitioners. It is worth $463.32M on the market and sold $326.28M over the last year.

Market cap
$463.32M
P/E ratio
None (reported a loss)
Annual sales
$326.28M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Brief updated
Nov 17, 2026

Brands and businesses behind EOLS

  • Jeuveau: It is an injectable aesthetic neurotoxin that earns revenue through direct product sales to licensed medical practitioners.
  • Evolysse: It is a line of hyaluronic acid dermal fillers sold directly to aesthetic clinics to generate product revenue.
  • Nuceiva: It is the international brand name for Jeuveau, generating export sales across European and Canadian markets.

EOLS’s flags, in plain English

Each flag is a number from Evolus’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 17, 2026.

Still Climbing

Sales up 39.4% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Wide Gross Margin

Gross margin of 64.5% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Insiders Hold

Insiders own 12.4% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Burning Cash

Losing money, profit margin of -9.6%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

2 more risk notes open with the free trial. Try it free for 7 days.

Questions about EOLS

How big is Evolus?

Evolus’ market cap is $463.32M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $326.28M: what customers paid the company over the last year, before any costs.

What is EOLS’s P/E ratio?

EOLS has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with EOLS?

The business relies on a single South Korean contract manufacturer for all supplies of its primary neurotoxin product. That is one risk on Evolus’ card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Evolus’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. EOLS’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card